Antiviral resistance

Although people living with human immunodeficiency virus (HIV-1) infections are routinely treated with antiretroviral (ARV) drug cocktails, the viral nucleic acid mutates into resistant forms, rendering ARV therapy ineffective. Learn from these resources about the recent advances in ARV therapy.

Original Articles

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

READ MORE

Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study

READ MORE

Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific

READ MORE

Infographics

Infographic - Overcoming Antiviral Resistance in People Living With HIV-1

Overcoming Antiviral Resistance in People Living With HIV-1

VIEW INFOGRAPHIC

KOL Commentaries

Prof. Andrew Carr comments on antiretroviral trials - HIV

Comments on Antiretroviral Trials
Watch Time: 4.03 min

WATCH VIDEO

E-learning

E-learning – Antiretroviral Resistance

E-learning – Antiretroviral Resistance

TAKE E-LEARNING

Start typing and press enter to search